

REMARKS

The Examiner has required restriction in the above-identified application and has divided the claims as follows:

- | | |
|------------|---|
| Group I | Claims 1-15, drawn to compounds, compositions and method of use for Formula (I) wherein T ^{ag} is a heterocyclic serotonin receptor selected from formula 1 or 2; |
| Group II | Claims 1-15, drawn to compounds, compositions and method of use for Formula (I) wherein T ^{ag} is a heterocyclic serotonin receptor selected from formula 3 or 11; |
| Group III | Claims 1-15, drawn to compounds, compositions and method of use for Formula (I) wherein T ^{ag} is a heterocyclic serotonin receptor selected from formula 4; |
| Group IV | Claims 1-15, drawn to compounds, compositions and method of use for Formula (I) wherein T ^{ag} is a heterocyclic serotonin receptor selected from formula 5 or 10; |
| Group V | Claims 1-15, drawn to compounds, compositions and method of use for Formula (I) wherein T ^{ag} is a heterocyclic serotonin receptor selected from formula 6; |
| Group VI | Claims 1-15, drawn to compounds, compositions and method of use for Formula (I) wherein T ^{ag} is a heterocyclic serotonin receptor selected from formula 7; |
| Group VII | Claims 1-15, drawn to compounds, compositions and method of use for Formula (I) wherein T ^{ag} is a heterocyclic serotonin receptor selected from formula 8; and |
| Group VIII | Claims 1-15, drawn to compounds, compositions and method of use for Formula (I) wherein T ^{ag} is a heterocyclic serotonin receptor selected from formula 9. |


The Office Action states that the inventions are distinct because of the following reasons, the inventions in Groups I through VIII are structurally dissimilar compounds, that they are made and used independently and that they would be expected to raise different issues of patentability, they are classified separately and require separate burdensome searches. Withdrawal of the restriction between Groups I-VIII is respectfully requested.

Applicants submit that the reasons offered by the Examiner are not sufficient to support a conclusion that the inventions are patentably distinct nor that a serious burden is placed on the Examiner if restriction is not required. The

restrictions are believed to be improper and it is respectfully requested that it be withdrawn.

In view of the foregoing, Applicants submit that the application is now in condition for examination on the merits. Early notification of such action is requested.

Respectfully submitted,



Mary K. VanAtten
Attorney for Applicants
Registration No. 39,408
Telephone 609/252-4379

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000

Date: April 24, 2003